Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Amgen
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- MARITIME-T2D-3
- status
- NOT_YET_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1300
- sponsor
- Amgen
- conditions
- Diabetes Mellitus, Type 2
- interventions
- DRUG: Maridebart cafraglutide; DRUG: Semaglutide
- start date
- 2026-11-02
- start date type
- ESTIMATED
- primary completion date
- 2028-09-04
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07866066
- Published
- Oct 8, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07866066
- Categories
- Diabetes Mellitus, Type 2
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials